American Stroke Association Releases Updated 2026 Stroke Guidelines

The American Stroke Association, a division of the American Heart Association (AHA), has unveiled its 2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke. These updated guidelines reflect significant advancements in stroke treatment and mark a milestone with the introduction of the first detailed recommendations for diagnosing and treating stroke in children.

Key changes include broadened eligibility for clot-removal procedures, the endorsement of the medication tenecteplase, and a strong emphasis on coordinated care systems designed to enhance patient outcomes.

Overview of Key Updates

The new guidelines supersede the 2018 edition and its 2019 update. Dr. Shyam Prabhakaran, who chaired the Writing Group, alongside Co-Vice Chairs Dr. Nestor R. Gonzalez and Dr. Kori S. Zachrison, highlighted that these updates integrate the most current evidence in acute ischemic stroke care, aiming to standardize treatment across diverse hospital settings.

"The updates incorporate the most recent evidence in acute ischemic stroke care, with the aim of standardizing treatment across various hospital settings."
— Dr. Shyam Prabhakaran, Writing Group Chair

Major revisions are concentrated in several critical areas:

• Expansion of eligibility for mechanical clot-removal (endovascular thrombectomy - EVT).
• Endorsement of tenecteplase as a clot-busting medication.
• Inclusion of specific guidance for pediatric stroke.
• Emphasis on mobile stroke units and regional stroke systems to accelerate care.

Pediatric Stroke: New Guidance

For the first time, these guidelines feature comprehensive recommendations for stroke in infants, children, and adolescents, spanning ages 28 days to 18 years.

Beyond the adult stroke warning signs (Face Drooping, Arm Weakness, Speech Difficulty, Time to Call 911), children may present with:

• Sudden severe headache
• New-onset seizures
• Sudden confusion or speech difficulty
• Sudden vision trouble
• Sudden difficulty walking or balance issues

Rapid magnetic resonance imaging (MRI) and angiography (MRA) are advised for quick differentiation of stroke types. Computed tomography (CT) is an acceptable alternative if MRI is not immediately accessible.

• Intravenous (IV) alteplase may be considered within 4.5 hours for eligible children.
• Mechanical clot-removal (EVT) by experienced neurointerventionalists may be effective for large-vessel blockages in children 6 years and older, typically within 6 hours of symptom onset. This treatment window can extend up to 24 hours if advanced imaging indicates salvageable brain tissue.

Enhancing Care Delivery and Diagnostics

The guidelines underscore the vital role of integrated regional stroke systems, which involve 9-1-1, emergency medical services (EMS), hospitals, and telemedicine networks.

Mobile Stroke Units are recognized for their effectiveness in expediting stroke recognition and treatment.

For patients with suspected large vessel occlusion (LVO), EMS should ideally transport them directly to thrombectomy-capable stroke centers (TSCs). If direct transport isn't feasible, efforts should concentrate on reducing transfer times from primary stroke centers to TSCs.

Hospitals are advised to complete an initial brain scan within 25 minutes of arrival to confirm an ischemic stroke and rule out brain hemorrhages. Advanced imaging techniques such as MRI or CT perfusion can assess brain tissue viability. For facilities lacking advanced perfusion imaging, the standard CT scoring system, ASPECTS, can be utilized to identify suitable candidates for clot-removal procedures.

Updated Treatment Modalities

The guidelines provide refreshed recommendations for both pharmacological and mechanical interventions.

Tenecteplase or alteplase are endorsed for administration within 4.5 hours of symptom onset. Notably, tenecteplase offers the advantage of a single-dose IV infusion method. Treatment with these medications may be considered up to 24 hours after symptom onset in select patients, provided advanced brain imaging reveals salvageable brain tissue.

EVT is recommended for major strokes caused by large-vessel blockages. Patients eligible for both clot-busting medications and EVT should receive both sequentially.

The recommendation for EVT has been extended up to 24 hours after symptom onset, now including some patients with large core infarcts identified by ASPECTS. Eligibility criteria have also expanded to include some individuals with blockages in the back of the brain (posterior circulation stroke) and those with mild or moderate preexisting disability within the first 6 hours of symptom onset. EVT is not routinely recommended for smaller blockages but may be considered within clinical trial settings.

Improving Patient Outcomes

The guidelines emphasize that coordinated systems of care are crucial for improving survival and recovery rates. Hospitals are encouraged to:

• Utilize reporting systems such as the American Stroke Association's Get With The Guidelines® - Stroke Registry.
• Expand access to telemedicine and advanced imaging.
• Establish transfer agreements between primary stroke centers and comprehensive stroke centers.

Streamlining processes from EMS dispatch to hospital arrival is projected to reduce treatment times by 30 to 60 minutes, which can significantly impact patient outcomes and disability levels.

The 2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke is slated for presentation at the 2026 International Stroke Conference in New Orleans.